VERTEX PHARMACEUTICALS INC / MA Form 4 December 18, 2015 **OMB APPROVAL** FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading BOGER JOSHUA S Issuer Symbol VERTEX PHARMACEUTICALS (Check all applicable) INC / MA [VRTX] (Last) (First) (Middle) 3. Date of Earliest Transaction X_ Director 10% Owner Other (specify Officer (give title (Month/Day/Year) below) below) C/O VERTEX 12/16/2015 PHARMACEUTICALS **INCORPORATED, 50 NORTHERN AVENUE** (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting BOSTON, MA 02210 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) 5. Amount of 6. 7. Nature of Transaction Disposed of (D) Ownership Indirect Security (Month/Day/Year) Execution Date, if Securities (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial any (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Code V Amount (D) Price Common 12/16/2015 Μ 10,400 \$35.64 275,684 D А Stock \$ Common 12/16/2015 S(1) 2,000 D 114.72 273,684 D Stock (2) (3) \$ Common S⁽¹⁾ 12/16/2015 2,600 D 115.72 271,084 D Stock (2) (4)

Common Stock	12/16/20)15	S <u>(1)</u>	4,400	D	\$ 116.47 (2) (5)	266,684	D		
Common Stock	12/16/20	015	S <u>(1)</u>	400	D	\$ 117.73 (2) (6)	266,284	D		
Common Stock	12/16/20)15	S <u>(1)</u>	1,000	D	\$ 118.81 (2) (7)	265,284	D		
Common Stock							13,286	Ι	401(k)	
Common Stock							122,700	Ι	Commo Stock he in trust	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) SEC 1474 (9-02)										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		4. Transacti Code (Instr. 8)	orDer Secu Acq or D (D)	urities uired (A) Disposed of tr. 3, 4,	6. Date Exer Expiration D (Month/Day/	ate	7. Title and 4 Underlying 5 (Instr. 3 and	Securities
							Date	Expiration	Title	Amount or
				Code V	(A)	(D)	Exercisable	Date	Thie	Number of Shares

Reporting Owners

Reporting Owner Name / AddressRelationshipDirector10% OwnerOfficerBOGER JOSHUA S
C/O VERTEX PHARMACEUTICALS INCORPORATEDXV

8 E S ()

50 NORTHERN AVENUE BOSTON, MA 02210

Signatures

Omar White, Attorney-In-Fact

12/18/2015

Date

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- (2) Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (3) Open market sales reported on this line occurred at a weighted average price of \$114.72 (range \$114.20 to \$115.19).
- (4) Open market sales reported on this line occurred at a weighted average price of \$115.72 (range \$115.20 to \$116.04).
- (5) Open market sales reported on this line occurred at a weighted average price of \$116.47 (range \$116.21 to \$117.15).
- (6) Open market sales reported on this line occurred at a weighted average price of \$117.73 (range \$117.42 to \$117.92).
- (7) Open market sales reported on this line occurred at a weighted average price of \$118.81 (range \$118.52 to \$119.21).
- (8) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. Y: Times New Roman; DISPLAY: inline">

SCHEDULE 13G

Item 1(a)	Name of Issuer: Comfort Systems USA Inc.						
1(b)	Address of Issuer	Address of Issuer's Principal Executive Offices:					
	675 Bering Drive Houston, TX 770						
Item 2(a)	Name of Person F	Riling:					
	Barrow, Hanley, I	Mewhinney & Strauss, LLC					
2(b)	Address of Princi	Address of Principal Business Office or, if none, Residence:					
	2200 Ross Avenu Dallas, TX 75201						
2(c)	Citizenship:	Citizenship:					
	A Delaware limited liability company						
2(d)	Title of Class of Securities						
	Common Stock						
2(e)	CUSIP Number:	199908104					
Item 3	If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:						
	(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);				
	(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);				
	(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);				
	(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);				
	(e)	þ	An investment adviser in accordance with \$240.13d-1(b)(1)(ii)(E);				

(f)	 An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	 A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
(h)	 A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	 A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	 Group, in a accordance with §240.13d-1(b)(1)(ii)(J).

Item 4	Ownership:			
	4(a)	Amount beneficially owned:		
	4(b)	Percent of Class:		
	4(c)	Number of shares as to which person has:		
	(i)	Sole power to vote or to direct the vote:		
	(ii)	Shared power to vote or to direct the vote:		
	(iii)	Sole power to dispose or to direct the disposition of:		
	(iv)	Shared power to dispose or to direct the disposition of:		
Item 5	Ownership of Five Po Yes.	ercent or Less of a Class:		
Item 6	The right to receive of from the sale of, the	Ownership of More than Five Percent on Behalf of Another Person: The right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock is held by certain clients of the reporting person, none of which has such right or power with respect to five percent or more of the common stock.		
Item 7		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: Not Applicable.		
Item 8	Identification and Cla Not Applicable.	Identification and Classification of Members of the Group: Not Applicable.		
Item 9	Notice of Dissolution Not Applicable.	n of Group:		
Item 10	Certification:			
	the securities referr business and were n changing or influence	e undersigned certifies that, to the best of its knowledge and belief, ed to above were acquired and are held in the ordinary course of ot acquired and are not held for the purpose of or with the effect of sing the control of the issuer of the securities and were not acquired connection with or as a participant in any transaction having that		

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Barrow, Hanley, Mewhinney & Strauss, LLC

By:

/s/ Patricia B. AndrewsName: Patricia B. AndrewsTitle: Chief Compliance and RiskOfficer

February 7, 2017